TW202038930A - 使用6,8-雙-苄硫基-辛酸之口服療法 - Google Patents

使用6,8-雙-苄硫基-辛酸之口服療法 Download PDF

Info

Publication number
TW202038930A
TW202038930A TW108147079A TW108147079A TW202038930A TW 202038930 A TW202038930 A TW 202038930A TW 108147079 A TW108147079 A TW 108147079A TW 108147079 A TW108147079 A TW 108147079A TW 202038930 A TW202038930 A TW 202038930A
Authority
TW
Taiwan
Prior art keywords
cancer
certain embodiments
bis
benzylthio
octanoic acid
Prior art date
Application number
TW108147079A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 Ｇ Ｌ 修爾
提摩西 Ｓ 帕爾迪
拉克瑪爾 波特居
Original Assignee
美商拉斐爾製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商拉斐爾製藥公司 filed Critical 美商拉斐爾製藥公司
Publication of TW202038930A publication Critical patent/TW202038930A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW108147079A 2018-12-20 2019-12-20 使用6,8-雙-苄硫基-辛酸之口服療法 TW202038930A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862782938P 2018-12-20 2018-12-20
US62/782,938 2018-12-20
US201962834478P 2019-04-16 2019-04-16
US62/834,478 2019-04-16

Publications (1)

Publication Number Publication Date
TW202038930A true TW202038930A (zh) 2020-11-01

Family

ID=71101630

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108147079A TW202038930A (zh) 2018-12-20 2019-12-20 使用6,8-雙-苄硫基-辛酸之口服療法

Country Status (11)

Country Link
US (1) US20220040133A1 (https=)
EP (1) EP3897606A4 (https=)
JP (1) JP2022514084A (https=)
KR (1) KR20210105913A (https=)
CN (1) CN113543779A (https=)
AU (1) AU2019405976A1 (https=)
CA (1) CA3121645A1 (https=)
IL (1) IL283609A (https=)
MX (1) MX2021007324A (https=)
TW (1) TW202038930A (https=)
WO (1) WO2020132401A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240033277A1 (en) * 2020-12-03 2024-02-01 New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Methods for treating autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
WO2009110859A1 (en) * 2008-03-04 2009-09-11 Robert Shorr Modulation of enzymatic structure, activity, and/or expression level
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
MA45865A (fr) * 2016-08-07 2021-04-14 Wistar Inst Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
WO2019055525A1 (en) * 2017-09-12 2019-03-21 Raj Selvaraj FORMULATION OF SOLID NANOPARTICLES OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD CURING
US20210000778A1 (en) * 2018-04-16 2021-01-07 Rafael Pharmaceuticals, Inc. Therapeutic methods and compositions for treating prostate cancer using 6,8-bis-benzylthio-octanoic acid
CN112469405A (zh) * 2018-07-23 2021-03-09 拉斐尔制药股份有限公司 使用6,8-双(苄硫基)辛酸治疗胰腺癌的治疗方法和组合物
US20220054445A1 (en) * 2018-12-20 2022-02-24 Rafael Pharmaceuticals, Inc. Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor
MX2021011250A (es) * 2019-03-19 2022-02-11 Rafael Pharmaceuticals Inc Metodos y composiciones terapeuticas para tratar linfoma usando acido 6,8-bis-benciltio-octanoico.

Also Published As

Publication number Publication date
KR20210105913A (ko) 2021-08-27
WO2020132401A1 (en) 2020-06-25
CN113543779A (zh) 2021-10-22
JP2022514084A (ja) 2022-02-09
AU2019405976A1 (en) 2021-06-24
US20220040133A1 (en) 2022-02-10
EP3897606A1 (en) 2021-10-27
EP3897606A4 (en) 2022-08-31
MX2021007324A (es) 2021-08-16
CA3121645A1 (en) 2020-06-25
IL283609A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
TWI305527B (en) Synthesis of 4-(amino)-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines
JP6445591B2 (ja) シロリムス及びその誘導体の複合体、それらの調製方法ならびにそれらを含有する医薬組成物
RU2498804C2 (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
RU2662819C2 (ru) Твердая дисперсия с улучшенной растворимостью, содержащая производное тетразола в качестве активного ингредиента
JP2021521222A (ja) ６，８−ビス−ベンジルチオ−オクタン酸を使用して前立腺癌を治療するための治療方法および組成物
JP2021523169A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
US20220054445A1 (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor
CN118750499A (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
TWI853841B (zh) 尼拉帕尼（niraparib）鹽
TWI825191B (zh) 尼拉帕尼（niraparib）游離鹼之結晶形
TW202038930A (zh) 使用6,8-雙-苄硫基-辛酸之口服療法
TW202222321A (zh) Ｍｃｌ—１抑制劑配製物
TW202038931A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
TWI845578B (zh) 用於治療癌症之口服愛萊諾迪肯（ｉｒｉｎｏｔｅｃａｎ）與Ｐ－ｇｐ抑制劑的醫療組合
WO2011003362A1 (zh) 13a-(S)去氧娃儿藤宁的盐、其制法和药物组合物与用途
WO2019230595A1 (ja) びまん性胃癌の治療剤
TW200536529A (en) Dosage forms and methods of treatment using VEGFR inhibitors
TW202114651A (zh) 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物
HK40120176A (zh) 尼拉帕利盐
US20220331279A1 (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and a glutaminase inhibitor
WO2026012350A1 (zh) 色烯酮类化合物的应用
WO2025248485A1 (en) Pharmaceutical compositions and methods of use thereof
HK40103034A (zh) 免疫调节剂的晶体形式
TW202114650A (zh) 6,8-雙(苄基磺醯基)辛酸之氘化衍生物